Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Citi
Federal Trade Commission
McKinsey
Moodys
Julphar
Teva
Cerilliant
Mallinckrodt
Colorcon

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,496,965

« Back to Dashboard

Which drugs does patent 8,496,965 protect, and when does it expire?

Patent 8,496,965 protects APRISO and is included in one NDA.

This patent has ten patent family members in nine countries.
Summary for Patent: 8,496,965
Title:Pellet formulation for the treatment of the intenstinal tract
Abstract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
Inventor(s): Otterbeck; Norbert (Uberlingen, DE)
Assignee: Dr. Falk Pharma GmbH (Freiburg, DE)
Application Number:13/586,585
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Drugs Protected by US Patent 8,496,965

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Valeant Pharms Intl APRISO mesalamine CAPSULE, EXTENDED RELEASE;ORAL 022301-001 Oct 31, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,496,965

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany197 32 903Jul 30, 1997

Non-Orange Book US Patents Family Members for Patent 8,496,965

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,277,412 Pellet-type formulation intended for treating the intestinal tract ➤ Sign Up
8,337,886 Pellet formulation for the treatment of the intestinal tract ➤ Sign Up
8,911,778 Pellet formulation for the treatment of the intestinal tract ➤ Sign Up
8,956,647 Pellet formulation for the treatment of the intestinal tract ➤ Sign Up
8,940,328 Pellet formulation for the treatment of the intestinal tract ➤ Sign Up
6,551,620 Pellet formulation for the treatment of the intestinal tract ➤ Sign Up
7,547,451 Pellet formulation for the treatment of the intestinal tract ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,496,965

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 977557 ➤ Sign Up
Japan 4088413 ➤ Sign Up
Japan 2001511441 ➤ Sign Up
Spain 2196556 ➤ Sign Up
European Patent Office 0977557 ➤ Sign Up
Denmark 0977557 ➤ Sign Up
Germany 59808642 ➤ Sign Up
Germany 19732903 ➤ Sign Up
Canada 2297832 ➤ Sign Up
Austria 241964 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Julphar
Mallinckrodt
US Department of Justice
Fish and Richardson
Covington
Harvard Business School
Accenture
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot